Are we closer to having drugs to treat muscle wasting disease?

The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise trai...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cachexia, sarcopenia and muscle sarcopenia and muscle, 2014-06, Vol.5 (2), p.83-87
Main Authors: Morley, John E., von Haehling, Stephan, Anker, Stefan D.
Format: Article
Language:English
Subjects:
Amyotrophic lateral sclerosis
Appetite
Cancer therapies
Clinical Nutrition
Disease
Drugs
Editorial
Food
Fractures
Geriatrics/Gerontology
Growth hormones
Heart failure
Hospitalization
Internal Medicine
Malnutrition
Medicine
Medicine & Public Health
Molecular Medicine
Mortality
Muscle function
Musculoskeletal system
Oncology
Pharmacology/Toxicology
Proteins
Quality of life
Sarcopenia
Studies
Testosterone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.
ISSN:2190-5991
2190-6009
DOI:10.1007/s13539-014-0149-7